What is the elimination half‑life of trazodone and bupropion (Wellbutrin) in typical adult patients with normal liver function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pharmaceutical Half-Life of Trazodone and Bupropion (Wellbutrin)

Trazodone has an elimination half-life of 7-13 hours in adults with normal liver function, while bupropion (Wellbutrin) has a shorter half-life of 5-9 hours in younger adults (20-45 years) that extends to 11-13 hours in elderly patients.

Trazodone Pharmacokinetics

Elimination Half-Life

  • The terminal elimination half-life of trazodone ranges from 7.3 to 13 hours in healthy adults with normal hepatic function 1, 2, 3.
  • A well-controlled study in 43 healthy subjects demonstrated a mean elimination half-life of 4.7 hours in young men (18-40 years), which increased to 8.2 hours in elderly men (60-76 years) 4.
  • Women showed similar age-related increases, with half-life extending from 5.9 hours in young women to 7.6 hours in elderly women 4.

Factors Affecting Trazodone Half-Life

  • Obesity significantly prolongs trazodone's half-life to 13.3 hours (compared to 5.9 hours in normal-weight individuals) due to increased volume of distribution, though clearance remains unchanged 4.
  • The biphasic elimination pattern includes a redistribution half-life of approximately 1 hour followed by the terminal elimination phase of 10-12 hours 1, 3.
  • Food intake does not alter the total bioavailability (63-65%) but delays absorption and reduces peak serum concentrations 2.

Clinical Implications for Trazodone

  • Trazodone is nearly completely metabolized hepatically through hydroxylation and oxidation to inactive metabolites 1.
  • Less than 0.13% of the administered dose is excreted unchanged in urine, indicating extensive hepatic metabolism 2.
  • Elderly men show reduced clearance (1.65 vs. 2.31 ml/min/kg in young men), necessitating potential dosage reduction during chronic therapy 4.

Bupropion (Wellbutrin) Pharmacokinetics

Elimination Half-Life

  • Bupropion has an elimination half-life of 5-9 hours in young healthy individuals (age 20-45 years) 5.
  • In elderly patients, the half-life extends to 11-13 hours 5.

Active Metabolites

  • Bupropion is extensively metabolized into three active metabolites: hydroxybupropion, threohydrobupropion, and erythrohydrobupropion, each with substantial antidepressant activity 6.
  • These active metabolites contribute to the overall pharmacological effect and may have longer half-lives than the parent compound 6.

Clinical Dosing Considerations

  • The maximum dose is 450 mg per day for immediate-release formulations and 400 mg per day for sustained-release formulations due to seizure risk 6.
  • Bupropion is the only antidepressant with no appreciable activity on serotonin, working primarily through norepinephrine and dopamine neurotransmitters 6.

Key Clinical Distinctions

Comparative Half-Life Summary

  • Trazodone: 7-13 hours (longer in elderly and obese patients) 1, 2, 3, 4
  • Bupropion: 5-9 hours (young adults) to 11-13 hours (elderly) 5

Practical Dosing Implications

  • Trazodone's longer half-life allows for once or twice-daily dosing, with steady-state achieved after approximately 5 half-lives (35-65 hours) 5.
  • Both medications require dose adjustments in elderly patients due to prolonged elimination 5, 4.
  • For trazodone, dosing should be based on ideal body weight in obese patients rather than total body weight due to the dramatically increased volume of distribution 4.

References

Research

Antidepressant properties of trazodone.

Clinical pharmacy, 1982

Research

Trazodone kinetics: effect of age, gender, and obesity.

Clinical pharmacology and therapeutics, 1987

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.